AAAAAA

   
Results: 1-25 | 26-36
Results: 1-25/36
PREVALENCE AND PROGNOSTIC-SIGNIFICANCE OF NEUROENDOCRINE DIFFERENTIATION IN COLORECTAL CARCINOMAS
Authors: LLOYD RV SCHROEDER G BAUMAN MD KROOK JE JIN L GOLDBERG RM FARR GH
Citation: Rv. Lloyd et al., PREVALENCE AND PROGNOSTIC-SIGNIFICANCE OF NEUROENDOCRINE DIFFERENTIATION IN COLORECTAL CARCINOMAS, Endocrine pathology, 9(1), 1998, pp. 35-42
SEQUENTIAL INTRAHEPATIC FLUORODEOXYURIDINE AND SYSTEMIC FLUOROURACIL PLUS LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL-CANCER CONFINED TO THE LIVER
Authors: OCONNELL MJ NAGORNEY DM BERNATH AM SCHROEDER G FITZGIBBONS RJ MAILLIARD JA BURCH P BOLTON JS COLONOTERO G KROOK JE
Citation: Mj. Oconnell et al., SEQUENTIAL INTRAHEPATIC FLUORODEOXYURIDINE AND SYSTEMIC FLUOROURACIL PLUS LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL-CANCER CONFINED TO THE LIVER, Journal of clinical oncology, 16(7), 1998, pp. 2528-2533
PROSPECTIVELY RANDOMIZED TRIAL OF POSTOPERATIVE ADJUVANT CHEMOTHERAPYIN PATIENTS WITH HIGH-RISK COLON-CANCER
Authors: OCONNELL MJ LAURIE JA KAHN M FITZGIBBONS RJ ERLICHMAN C SHEPHERD L MOERTEL CG KOCHA WI PAZDUR R WIEAND HS RUBIN J VUKOV AM DONOHUE JH KROOK JE FIGUEREDO A
Citation: Mj. Oconnell et al., PROSPECTIVELY RANDOMIZED TRIAL OF POSTOPERATIVE ADJUVANT CHEMOTHERAPYIN PATIENTS WITH HIGH-RISK COLON-CANCER, Journal of clinical oncology, 16(1), 1998, pp. 295-300
ACUTE TREATMENT-RELATED DIARRHEA DURING POSTOPERATIVE ADJUVANT THERAPY FOR HIGH-RISK RECTAL-CARCINOMA
Authors: MILLER RC MARTENSON JA SARGENT DJ KAHN MJ KROOK JE
Citation: Rc. Miller et al., ACUTE TREATMENT-RELATED DIARRHEA DURING POSTOPERATIVE ADJUVANT THERAPY FOR HIGH-RISK RECTAL-CARCINOMA, International journal of radiation oncology, biology, physics, 41(3), 1998, pp. 593-598
COMBINED LEVAMISOLE WITH RECOMBINANT INTERLEUKIN-2 (IL-2) IN PATIENTSWITH ADVANCED RENAL-CELL CARCINOMA - A PHASE-II STUDY
Authors: CREAGAN ET HESTORRF RD SUMAN VJ MAILLIARD JA NAIR S KROOK JE KUGLER JW MARSCHKE RF MICHALAK JC TSCHETTER LK
Citation: Et. Creagan et al., COMBINED LEVAMISOLE WITH RECOMBINANT INTERLEUKIN-2 (IL-2) IN PATIENTSWITH ADVANCED RENAL-CELL CARCINOMA - A PHASE-II STUDY, American journal of clinical oncology, 21(2), 1998, pp. 139-141
THE ROLE OF THE 5-HT3 ANTAGONISTS ONDANSETRON AND DOLASETRON IN THE CONTROL OF DELAYED-ONSET NAUSEA AND VOMITING IN PATIENTS RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY
Authors: PATER JL LOFTERS WS ZEE B DEMPSEY E WALDE D MOQUIN JP WILSON K HOSKINS P GUEVIN RM VERMA S NAVARI R KROOK JE HAINSWORTH J PALMER M CHIN C
Citation: Jl. Pater et al., THE ROLE OF THE 5-HT3 ANTAGONISTS ONDANSETRON AND DOLASETRON IN THE CONTROL OF DELAYED-ONSET NAUSEA AND VOMITING IN PATIENTS RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY, Annals of oncology, 8(2), 1997, pp. 181-185
PHASE-III DOUBLE-BLIND COMPARISON OF DOLASETRON MESYLATE AND ONDANSETRON AND AN EVALUATION OF THE ADDITIVE ROLE OF DEXAMETHASONE IN THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING DUE TO MODERATELY EMETOGENIC CHEMOTHERAPY
Authors: LOFTERS WS PATER JL ZEE B DEMPSEY E WALDE D MOQUIN JP WILSON K HOSKINS P GUEVIN RM VERMAN S NAVARI R KROOK JE HAINSWORTH J PALMER M CHIN C
Citation: Ws. Lofters et al., PHASE-III DOUBLE-BLIND COMPARISON OF DOLASETRON MESYLATE AND ONDANSETRON AND AN EVALUATION OF THE ADDITIVE ROLE OF DEXAMETHASONE IN THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING DUE TO MODERATELY EMETOGENIC CHEMOTHERAPY, Journal of clinical oncology, 15(8), 1997, pp. 2966-2973
PROSPECTIVELY RANDOMIZED NORTH CENTRAL CANCER-TREATMENT GROUP TRIAL OF INTENSIVE-COURSE FLUOROURACIL COMBINED WITH THE L-ISOMER OF INTRAVENOUS LEUCOVORIN, ORAL LEUCOVORIN, OR INTRAVENOUS LEUCOVORIN FOR THE TREATMENT OF ADVANCED COLORECTAL-CANCER
Authors: GOLDBERG RM HATFIELD AK KAHN M SARGENT DJ KNOST JA OCONNELL MJ KROOK JE MAILLIARD JA WIESENFELD M SCHAEFER PL TIRONA MT MOERTEL CG
Citation: Rm. Goldberg et al., PROSPECTIVELY RANDOMIZED NORTH CENTRAL CANCER-TREATMENT GROUP TRIAL OF INTENSIVE-COURSE FLUOROURACIL COMBINED WITH THE L-ISOMER OF INTRAVENOUS LEUCOVORIN, ORAL LEUCOVORIN, OR INTRAVENOUS LEUCOVORIN FOR THE TREATMENT OF ADVANCED COLORECTAL-CANCER, Journal of clinical oncology, 15(11), 1997, pp. 3320-3329
EVALUATION OF INTRAVENOUS 6-THIOGUANINE AS FIRST-LINE CHEMOTHERAPY INWOMEN WITH METASTATIC BREAST-CANCER
Authors: INGLE JN TWITO DI SUMAN VJ KROOK JE MAILLIARD JA WINDSCHITL HE MARSCHKE RF
Citation: Jn. Ingle et al., EVALUATION OF INTRAVENOUS 6-THIOGUANINE AS FIRST-LINE CHEMOTHERAPY INWOMEN WITH METASTATIC BREAST-CANCER, American journal of clinical oncology, 20(1), 1997, pp. 69-72
RANDOMIZED TRIAL OF RADIATION-THERAPY (RT) PLUS DIBROMODULCITOL (DBD)VERSUS RT PLUS BCNU IN HIGH-GRADE ASTROCYTOMA
Authors: ELLIOTT TE DINAPOLI RP OFALLON JR KROOK JE EARLE JD MORTON RF LEVITT R TSCHETTER LK SCHEITHAUER BW PFEIFLE DM TWITO DI NELIMARK RA
Citation: Te. Elliott et al., RANDOMIZED TRIAL OF RADIATION-THERAPY (RT) PLUS DIBROMODULCITOL (DBD)VERSUS RT PLUS BCNU IN HIGH-GRADE ASTROCYTOMA, Journal of neuro-oncology, 33(3), 1997, pp. 239-250
A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF ADJUVANT RADIATION-THERAPY AND CHEMOTHERAPY FOR RESECTABLE RECTAL-CANCER - RESPONSE
Authors: GELBER RD GOLDHIRSCH A COLE BF KROOK JE
Citation: Rd. Gelber et al., A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF ADJUVANT RADIATION-THERAPY AND CHEMOTHERAPY FOR RESECTABLE RECTAL-CANCER - RESPONSE, Journal of the National Cancer Institute, 88(22), 1996, pp. 1686-1686
A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF ADJUVANT RADIATION-THERAPY AND CHEMOTHERAPY FOR RESECTABLE RECTAL-CANCER
Authors: GELBER RD GOLDHIRSCH A COLE BF WIEAND HS SCHROEDER G KROOK JE
Citation: Rd. Gelber et al., A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF ADJUVANT RADIATION-THERAPY AND CHEMOTHERAPY FOR RESECTABLE RECTAL-CANCER, Journal of the National Cancer Institute, 88(15), 1996, pp. 1039-1045
OCTREOTIDE AS FIRST-LINE TREATMENT FOR WOMEN WITH METASTATIC BREAST-CANCER
Authors: INGLE JN KARDINAL CG SUMAN VJ KROOK JE HATFIELD AK
Citation: Jn. Ingle et al., OCTREOTIDE AS FIRST-LINE TREATMENT FOR WOMEN WITH METASTATIC BREAST-CANCER, Investigational new drugs, 14(2), 1996, pp. 235-237
COMPARISON OF ESTROGEN-RECEPTOR DETERMINATIONS BY A BIOCHEMICAL LIGAND-BINDING ASSAY AND IMMUNOHISTOCHEMICAL STAINING WITH MONOCLONAL-ANTIBODY ER1D5 IN FEMALES WITH LYMPH-NODE POSITIVE BREAST-CARCINOMA ENTEREDON 2 PROSPECTIVE CLINICAL-TRIALS
Authors: ALBERTS SR INGLE JN ROCHE PR CHA SS WOLD LE FARR GH KROOK JE WIEAND HS
Citation: Sr. Alberts et al., COMPARISON OF ESTROGEN-RECEPTOR DETERMINATIONS BY A BIOCHEMICAL LIGAND-BINDING ASSAY AND IMMUNOHISTOCHEMICAL STAINING WITH MONOCLONAL-ANTIBODY ER1D5 IN FEMALES WITH LYMPH-NODE POSITIVE BREAST-CARCINOMA ENTEREDON 2 PROSPECTIVE CLINICAL-TRIALS, Cancer, 78(4), 1996, pp. 764-772
A PHASE-III EVALUATION OF A SOMATOSTATIN ANALOG (OCTREOTIDE) IN THE TREATMENT OF PATIENTS WITH ASYMPTOMATIC ADVANCED COLON-CARCINOMA - REPLY
Authors: GOLDBERG RM WIEAND HS KROOK JE SCHUTT AJ VEEDER MH MAILLAIRD JA DALTON RJ
Citation: Rm. Goldberg et al., A PHASE-III EVALUATION OF A SOMATOSTATIN ANALOG (OCTREOTIDE) IN THE TREATMENT OF PATIENTS WITH ASYMPTOMATIC ADVANCED COLON-CARCINOMA - REPLY, Cancer, 77(9), 1996, pp. 1956-1957
CONTROLLED CLINICAL-TRIAL OF INTERFERON-GAMMA AS POSTOPERATIVE SURGICAL ADJUVANT THERAPY FOR COLON-CANCER
Authors: WIESENFELD M OCONNELL MJ WIEAND HS GONCHOROFF NJ DONOHUE JH FITZGIBBONS RJ KROOK JE MAILLIARD JA GERSTNER JB PAZDUR R
Citation: M. Wiesenfeld et al., CONTROLLED CLINICAL-TRIAL OF INTERFERON-GAMMA AS POSTOPERATIVE SURGICAL ADJUVANT THERAPY FOR COLON-CANCER, Journal of clinical oncology, 13(9), 1995, pp. 2324-2329
PENTOXIFYLLINE FOR TREATMENT OF CANCER ANOREXIA AND CACHEXIA - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Authors: GOLDBERG RM LOPRINZI CL MAILLIARD JA OFALLON JR KROOK JE GHOSH C HESTORFF RD CHONG SF REUTER NF SHANAHAN TG
Citation: Rm. Goldberg et al., PENTOXIFYLLINE FOR TREATMENT OF CANCER ANOREXIA AND CACHEXIA - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, Journal of clinical oncology, 13(11), 1995, pp. 2856-2859
EVALUATION OF IFOSFAMIDE PLUS MESNA AS FIRST-LINE CHEMOTHERAPY IN WOMEN WITH METASTATIC BREAST-CANCER
Authors: INGLE JN KROOK JE MAILLIARD JA HARTMANN LC WIEAND HS
Citation: Jn. Ingle et al., EVALUATION OF IFOSFAMIDE PLUS MESNA AS FIRST-LINE CHEMOTHERAPY IN WOMEN WITH METASTATIC BREAST-CANCER, American journal of clinical oncology, 18(6), 1995, pp. 498-501
PHASE-II TRIAL OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN IN ADVANCED RECURRENT ENDOMETRIAL CARCINOMA
Authors: LONG HJ LANGDON RM CHA SS VEEDER MH PFEIFLE DM KROOK JE EBBERT LP TSCHETTER LK ROSHON SG
Citation: Hj. Long et al., PHASE-II TRIAL OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN IN ADVANCED RECURRENT ENDOMETRIAL CARCINOMA, Gynecologic oncology, 58(2), 1995, pp. 240-243
PHASE-II EVALUATION OF RECOMBINANT INTERFERON-ALPHA AND BCNU IN RECURRENT GLIOMA
Authors: BUCKNER JC BROWN LD KUGLER JW CASCINO TL KROOK JE MAILLIARD JA KARDINAL CG TSCHETTER LK OFALLON JR SCHEITHAUER BW
Citation: Jc. Buckner et al., PHASE-II EVALUATION OF RECOMBINANT INTERFERON-ALPHA AND BCNU IN RECURRENT GLIOMA, Journal of neurosurgery, 82(3), 1995, pp. 430-435
A PHASE-III EVALUATION OF A SOMATOSTATIN ANALOG (OCTREOTIDE) IN THE TREATMENT OF PATIENTS WITH ASYMPTOMATIC ADVANCED COLON-CARCINOMA
Authors: GOLDBERG RM MOERTEL CG WIEAND HS KROOK JE SCHUTT AJ VEEDER MH MAILLIARD JA DALTON RJ
Citation: Rm. Goldberg et al., A PHASE-III EVALUATION OF A SOMATOSTATIN ANALOG (OCTREOTIDE) IN THE TREATMENT OF PATIENTS WITH ASYMPTOMATIC ADVANCED COLON-CARCINOMA, Cancer, 76(6), 1995, pp. 961-966
P53 GENE-EXPRESSION IN NODE-POSITIVE BREAST-CANCER - RELATIONSHIP TO DNA-PLOIDY AND PROGNOSIS
Authors: CUNNINGHAM JM INGLE JN JUNG SH CHA SS WOLD LE FARR G WITZIG TE KROOK JE WIEAND HS KOVACH JS
Citation: Jm. Cunningham et al., P53 GENE-EXPRESSION IN NODE-POSITIVE BREAST-CANCER - RELATIONSHIP TO DNA-PLOIDY AND PROGNOSIS, Journal of the National Cancer Institute, 86(24), 1994, pp. 1871-1873
PROSPECTIVE EVALUATION OF PROGNOSTIC VARIABLES FROM PATIENT-COMPLETEDQUESTIONNAIRES
Authors: LOPRINZI CL LAURIE JA WIEAND HS KROOK JE NOVOTNY PJ KUGLER JW BARTEL J LAW M BATEMAN M KLATT NE DOSE AM ETZELL PS NELIMARK RA MAILLIARD JA MOERTEL CG
Citation: Cl. Loprinzi et al., PROSPECTIVE EVALUATION OF PROGNOSTIC VARIABLES FROM PATIENT-COMPLETEDQUESTIONNAIRES, Journal of clinical oncology, 12(3), 1994, pp. 601-607
CONTROLLED EVALUATION OF 3 DRUG-COMBINATION REGIMENS VERSUS FLUOROURACIL ALONE FOR THE THERAPY OF ADVANCED GASTRIC-CANCER
Authors: CULLINAN SA MOERTEL CG WIEAND HS OCONNELL MJ POON MA KROOK JE MAILLIARD JA TSCHETTER LK
Citation: Sa. Cullinan et al., CONTROLLED EVALUATION OF 3 DRUG-COMBINATION REGIMENS VERSUS FLUOROURACIL ALONE FOR THE THERAPY OF ADVANCED GASTRIC-CANCER, Journal of clinical oncology, 12(2), 1994, pp. 412-416
MEASURABLE OR ASSESSABLE DISEASE IN LUNG-CANCER TRIALS - DOES IT MATTER
Authors: JETT JR SU JQ KROOK JE GOLDBERG RM KUGLER JW
Citation: Jr. Jett et al., MEASURABLE OR ASSESSABLE DISEASE IN LUNG-CANCER TRIALS - DOES IT MATTER, Journal of clinical oncology, 12(12), 1994, pp. 2677-2681
Risultati: 1-25 | 26-36